Ring therapeutics

This biotechnology firm, headquartered in Cambridge, Massachusetts, is dedicated to the discovery and development of Anellovector™ therapeutics, aiming to maximize the potential of gene therapy. The company is at the forefront of creating the first redosable and targetable gene therapy platform by leveraging the biology of the human commensal virome. Their work extends the applications of gene therapy beyond gene replacement, allowing for a broader range of modalities and mechanisms to treat diseases that were previously untreatable. They are also developing anellovirus vectors for the safe and effective delivery of diverse modalities to target cells and tissues.